CN115769840B - Formula milk powder and preparation method thereof - Google Patents
Formula milk powder and preparation method thereof Download PDFInfo
- Publication number
- CN115769840B CN115769840B CN202211528939.6A CN202211528939A CN115769840B CN 115769840 B CN115769840 B CN 115769840B CN 202211528939 A CN202211528939 A CN 202211528939A CN 115769840 B CN115769840 B CN 115769840B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- formula
- powder
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 91
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000006041 probiotic Substances 0.000 claims abstract description 36
- 235000018291 probiotics Nutrition 0.000 claims abstract description 36
- 235000020256 human milk Nutrition 0.000 claims abstract description 28
- 210000004251 human milk Anatomy 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 239000003921 oil Substances 0.000 claims abstract description 23
- 235000019198 oils Nutrition 0.000 claims abstract description 23
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 23
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 23
- 235000020185 raw untreated milk Nutrition 0.000 claims abstract description 20
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 15
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 235000021119 whey protein Nutrition 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 9
- 239000005862 Whey Substances 0.000 claims abstract description 8
- 239000004519 grease Substances 0.000 claims abstract description 8
- 239000002285 corn oil Substances 0.000 claims abstract description 6
- 235000005687 corn oil Nutrition 0.000 claims abstract description 6
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 6
- 239000003549 soybean oil Substances 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 4
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 24
- 239000011707 mineral Substances 0.000 claims description 24
- 235000010755 mineral Nutrition 0.000 claims description 24
- 235000015097 nutrients Nutrition 0.000 claims description 24
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 23
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims description 22
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 22
- 230000001954 sterilising effect Effects 0.000 claims description 20
- 229940088594 vitamin Drugs 0.000 claims description 17
- 229930003231 vitamin Natural products 0.000 claims description 17
- 235000013343 vitamin Nutrition 0.000 claims description 17
- 239000011782 vitamin Substances 0.000 claims description 17
- 235000013336 milk Nutrition 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000001694 spray drying Methods 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 12
- 230000000529 probiotic effect Effects 0.000 claims description 12
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
- 102000011632 Caseins Human genes 0.000 claims description 5
- 108010076119 Caseins Proteins 0.000 claims description 5
- 235000019743 Choline chloride Nutrition 0.000 claims description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
- 229960003178 choline chloride Drugs 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 235000021247 β-casein Nutrition 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 238000007580 dry-mixing Methods 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 235000019175 phylloquinone Nutrition 0.000 claims description 3
- 239000011772 phylloquinone Substances 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 3
- 229960001898 phytomenadione Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229940083466 soybean lecithin Drugs 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 238000013329 compounding Methods 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 claims 3
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 9
- 229930195729 fatty acid Natural products 0.000 abstract description 9
- 239000000194 fatty acid Substances 0.000 abstract description 9
- 150000004665 fatty acids Chemical class 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 abstract 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 abstract 1
- 235000019484 Rapeseed oil Nutrition 0.000 abstract 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 description 20
- 230000035764 nutrition Effects 0.000 description 20
- 238000000855 fermentation Methods 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 19
- 238000002156 mixing Methods 0.000 description 17
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 210000003608 fece Anatomy 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 235000020247 cow milk Nutrition 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000020191 long-life milk Nutrition 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000020200 pasteurised milk Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940005605 valeric acid Drugs 0.000 description 3
- 229940062827 2'-fucosyllactose Drugs 0.000 description 2
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 description 2
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 238000004977 Hueckel calculation Methods 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- -1 compound vitamin Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010813 internal standard method Methods 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000002310 Achlorhydria Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 206010071061 Small intestinal bacterial overgrowth Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019581 fat taste sensations Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000007142 small intestinal bacterial overgrowth Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Dairy Products (AREA)
Abstract
The invention provides a formula milk powder and a preparation method thereof, wherein the formula milk powder comprises the following raw materials in parts by weight based on 1000 parts by weight of the total formula milk powder: 0.01-4.5 parts of breast milk oligosaccharide, 890-3800 parts of raw milk, 0-480 parts of lactose, 0-540 parts of desalted whey powder, 0-350 parts of skim milk powder, 80-80 parts of whey protein powder WPC, 34-120 parts of whey protein powder WPC, 0-0.18 part of probiotics, 0-0.8 part of nucleotide, 0-170 parts of structural grease OPO, 0-150 parts of high oleic sunflower seed oil, 0-50 parts of corn oil, 0-50 parts of low erucic acid rapeseed oil, 0-80 parts of soybean oil and the like. The formula milk powder provided by the invention provides a solution for improving intestinal microenvironment health, such as reducing branched chain fatty acid.
Description
Technical Field
The invention relates to the technical field of prebiotics, in particular to formula milk powder and a preparation method thereof.
Background
Breast milk oligosaccharides are complex mixed oligosaccharides present in breast milk, and are one of the important components in breast milk. Breast milk oligosaccharides stimulate the growth of beneficial bacteria in the intestinal tract and inhibit the growth of harmful bacteria. 2'-Fucosyllactose (2' -Fucosyl lactose,2 'FL) is the highest content of breast milk oligosaccharides in breast milk, and has been approved as a nutritional supplement for children's products; lactose-N-neotetraose (LNnT) is one of the highest content of neutral sugar chain core HMO in breast milk. Currently, commercially available LNnT is prepared via microbial fermentation, and the structure is determined by mass spectrometry and nuclear magnetic resonance to have the same structure as that of oligosaccharides found in human milk.
The metabolites in the intestine have small amounts of branched fatty acids (BCFA) such as isobutyric acid and isovaleric acid. Unlike acetic acid, propionic acid and butyric acid, isobutyric acid and isovaleric acid are metabolites of proteins. The reduction of isobutyric and isovaleric acids can be seen as a positive effect from protein fermentation to fiber fermentation. These branched-chain fatty acids are considered as marker substances for colonic protein fermentation, which process also produces other metabolites such as ammonia, phenol, p-cresol, or biogenic amines, which can cause damage to cells in the small intestine environment. High levels of isovaleric acid in the feces are associated with depression and cortisol levels in humans.
The total breast-fed infant had lower levels of isobutyric acid and isovaleric acid measured in the faeces compared to the infant not receiving breast-feeding. The presence of higher branched fatty acids in the feces, such as valeric acid, isobutyric acid, and isovaleric acid, indicates that the protein uptake is lower or there is excessive protein intake in the infant meal fed group. These metabolites may also result in higher levels of bacteroides and clostridia responsible for protein breakdown in infant feces from infant formulas. The energy gain of infants fed with the infant formulas is more dependent on protein metabolism because the level of protein catabolites in the feces of the infant formulas is higher, probably also because the infant formulas do not contain breast milk oligosaccharides and therefore the presence of carbohydrates is lower.
Research shows that in infant fecal culture systems fed by breast milk and formula powder, when fermentable carbohydrates are absent, metabolites of protein fermentation are mainly produced; when various fermentable carbohydrates are added, the protein metabolites decrease in content. The higher short chain fatty acid in the excrement of the formula powder feeding group can have an influence on the metabolism of infants. Studies have also shown that overweight adults and children have an increased fecal short chain fatty acids than lean, peer persons and are associated with other metabolic risk factors.
For adults, if gastric acid is deficient, protein digestion is inadequate and the intestinal tract is prone to the production of spoiled short chain fatty acids. Spoilage short chain fatty acids are formed by anaerobic bacterial fermentation of undigested branched chain amino acids, including valeric acid, isovaleric acid, isobutyric acid. Abnormal elevation of spoiled short chain fatty acids indicates protein dyspepsia, suggesting a potential achlorhydria, pancreatic insufficiency, malabsorption, and intestinal bacterial hyperproliferation (SIBO). In addition, in cancer research, metabolite analysis of colorectal cancer shows that branched chain amino acids, phenylalanine, and the like are significantly increased in early stages of the disease. Branched fatty acids such as isovaleric acid are increasing with the progression of the disease.
At present, in the fields of infant formula powder, complementary food, nutritional supplements and the like, a solution for improving intestinal microenvironment health, such as reducing branched-chain fatty acids such as isobutyric acid, isovaleric acid and the like is needed. In the area of children, adolescents and adults over 3 years of age, solutions are also needed to alleviate intestinal discomfort and to increase the ability of themselves to fight pathogenic bacteria such as ETEC infection.
Disclosure of Invention
It is an object of the present invention to provide a formula.
The invention also aims at providing a preparation method of the formula milk powder.
In order to achieve the above purpose, in one aspect, the present invention provides a formula, wherein the formula comprises the following raw materials in parts by weight based on 1000 parts by weight of the total formula: 0.01-4.5 parts of breast milk oligosaccharide (HMOs), 890-3800 parts of raw milk, 0-480 parts of lactose, 0-540 parts of desalted whey powder, 0-350 parts of skim milk powder, 80-80 parts of whey protein powder WPC, 34-120 parts of whey protein powder WPC, 0-0.18 part of probiotics, 0-170 parts of structural grease OPO, 0-150 parts of high oleic sunflower seed oil, 0-50 parts of corn oil, 0-50 parts of canola oil, 0-80 parts of soybean oil, 0-45 parts of alpha-lactalbumin, 0-23 parts of beta-casein, 1-2.5 parts of soybean lecithin, 0-30 parts of fructo-oligosaccharide, 0-90 parts of galacto-oligosaccharide syrup, 0-5 parts of anhydrous butter, 0-0.8 parts of nucleotide, 1-5 parts of vitamin nutrition, 0-3 parts of choline chloride, 0-2 parts of mineral A and 1-18 parts of mineral B; wherein, the mineral A is selected from the combination of mineral salts of one or more of copper, iron, magnesium, iodine, selenium, manganese and zinc, and the mineral B is selected from the combination of mineral salts of one or more of calcium, phosphorus, potassium and sodium.
According to some embodiments of the invention, wherein the human milk oligosaccharide comprises human milk oligosaccharide LNnT, wherein the human milk oligosaccharide LNnT is present in an amount of 0.01 to 4.5 parts by weight.
According to some embodiments of the invention, wherein the preparation of the raw materials further comprises: 0.20 to 2.04 parts by weight of inositol, 0 to 0.65 part by weight of taurine, 0.06 to 0.5 part by weight of L-carnitine, 3 to 18 parts by weight of DHA and 3 to 18 parts by weight of ARA.
According to some embodiments of the invention, wherein the vitamin nutrient is selected from the group consisting of vitamin a, vitamin D, vitamin E, vitamin K1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, pantothenic acid, and biotin.
The vitamin nutrient and various mineral substances in the formula can adopt a composite nutrient composition of nutrient components meeting the national standard, different addition amounts can be used according to different formulas, and the specific addition mode can be carried out by referring to the conventional operation in the field.
Preferably, the formula milk powder can selectively adopt any one or any combination of the following compound nutrient components (per gram content; each index is calculated according to the middle value of the adding range; basically, the condition that the content of all indexes is simultaneously maximum) if the compound nutrient is added according to the requirement:
vitamin a: 1300-4000. Mu.gRE
Vitamin D: 24-60 mug
Vitamin E: 13-41 mg alpha-TE
Vitamin K1: 200-550 mug
Vitamin B1: 2600-6500 mug
Vitamin B2: 600-3000 mug
Vitamin B6: 1200-4000 mug
Vitamin B12: 2-14.0 mug
Nicotinamide: 12000-30000 mug
Folic acid: 300-653 mu g
Pantothenic acid: 8750-16230 mug
Biotin: 56-150 mug.
According to some embodiments of the invention, wherein the mineral content (per gram content) is:
sodium: 30-400 mg
Potassium: 63-400 mg
Copper: 2200-5540 mug
Magnesium: 133-400 mg
Iron: 23-95 mg
Zinc: 25-52 mg
Calcium: 110-300 mg
Phosphorus: 75-200 mg
Iodine: 200-1592 mug
Selenium: 16-48 mu g
Manganese: 16-547 mug.
According to some embodiments of the invention, wherein the probiotic is selected from: one or more of Bifidobacterium animalis subspecies BB-12, bifidobacterium infantis YLGB-1496, bifidobacterium animalis subspecies HN019 and Bifidobacterium lactis BL-99.
According to some embodiments of the invention, the bifidobacterium infantis YLGB-1496 is bifidobacterium infantis with a accession number of CGMCC No. 21109.
According to some embodiments of the invention, the bifidobacterium lactis BL-99 is bifidobacterium lactis with a preservation number of CGMCC No. 15650.
According to some embodiments of the invention, wherein the probiotic is bifidobacterium lactis BL-99.
According to some embodiments of the invention, wherein the formula contains breast milk oligosaccharide LNnT in an amount of 142.9-428.6mg/100g of powder per 100g of formula; preferably 178.6-392.9mg/100g of powder.
According to some embodiments of the invention, wherein the formula contains probiotics in an amount of 10 per gram of formula 6 -2×10 12 CFU; preferably 10 8 -2×10 10 CFU。
According to some embodiments of the invention, wherein the formula is an infant formula for reducing branched short chain fatty acids.
The infant formula milk powder containing LNnT as a single active component has the effect of reducing branched chain short chain fatty acid in intestinal tracts.
According to a specific embodiment of the invention, the infant formula of the invention may be an infant formula or a baby formula.
According to a specific embodiment of the present invention, the infant formula of the present invention may comprise conventional components of infant formulas in addition to the probiotics and the breast milk oligosaccharides.
According to some embodiments of the invention, the branched short chain fatty acid is isovaleric acid.
In another aspect, the invention also provides a preparation method of the formula milk powder, which comprises the following steps: wet compounding, homogenizing, concentrating, sterilizing, spray drying, dry mixing and packaging.
According to some specific embodiments of the present invention, the wet-process batching includes homogenizing and sterilizing raw milk, and sequentially adding powder raw materials, grease raw materials, vitamin nutrients, mineral raw materials and breast milk oligosaccharides to obtain a mixed feed liquid; the powder raw material is other solid raw materials except breast milk oligosaccharide, vitamin nutrient and mineral raw materials.
According to some embodiments of the invention, wherein the wet-process formulation comprises the steps of:
1) Rough filtration of cow milk: filtering raw milk, degassing, preheating, and separating impurities by a separator;
2) Homogenizing and sterilizing cow milk: homogenizing one part of raw milk after removing impurities in a homogenizer and the other part of raw milk after removing impurities in the homogenizer, mixing the two parts in a mixing tank after homogenizing, and sterilizing;
3) Powder adding: adding various powder raw materials into a mixing tank according to a formula;
4) Melting and oil preparing: after the grease raw materials are dissolved, adding the grease raw materials into a mixing tank;
5) Nutrient dissolution and addition: respectively dissolving vitamin nutrients and mineral raw materials with purified water, and sequentially adding the dissolved vitamin nutrients and mineral raw materials into a mixing tank to obtain mixed feed liquid;
6) LNnT dissolution addition: and 5) dissolving the LNnT raw material with part of the mixed liquor in the step 5), and adding the dissolved LNnT raw material into a mixing tank to obtain the mixed liquor containing LNnT.
According to some embodiments of the invention, wherein the wet-process formulation comprises the steps of:
1) Rough filtration of cow milk: the cow milk is subjected to coarse filtration and degassing by a balance cylinder, is preheated by a plate heat exchanger, and is separated from impurities by a separator;
2) Homogenizing and sterilizing cow milk: part of raw milk after removing impurities enters a homogenizer for homogenization and the other part of raw milk is not homogenized, and the raw milk and the homogenized raw milk are mixed and enter a sterilization system for sterilization;
3) Powder adding: the powder raw materials are metered according to the formula, then are added into a powder mixing tank in a unified way through an air conveying system, and are sucked into the mixing tank through a vacuum system;
4) Melting and oil preparing: placing the grease raw materials specified in the formula into an oil melting room according to the formula requirement, keeping the temperature of the oil melting room at 50-90 ℃, after the oil is melted, pumping the mixed oil into a mixed oil storage tank, and pumping the mixed oil into the mixed oil tank through an oil pump according to the formula requirement;
5) Nutrient dissolution and addition: respectively dissolving vitamin nutrients and mineral raw materials with purified water, and sequentially adding the dissolved vitamin nutrients and mineral raw materials into a mixing tank to obtain mixed feed liquid;
6) LNnT dissolution addition: and 5) dissolving the LNnT raw material with part of the mixed liquor in the step 5), and adding the dissolved LNnT raw material into a mixing tank to obtain the mixed liquor containing LNnT.
According to some embodiments of the invention, the method further comprises the step of filtering the resulting LNnT-containing mixed liquor.
According to some embodiments of the invention, the homogenizing comprises homogenizing the LNnT-containing mixed liquor with a homogenizer.
According to some embodiments of the invention, the homogenizing further comprises cooling the homogenized mixed liquor to below 20 ℃.
According to some embodiments of the invention, the concentrating and sterilizing includes sterilizing the mixed liquor (preferably the homogenized mixed liquor or the cooled mixed liquor) containing LNnT at 83 ℃ for 25 seconds or more to obtain concentrated and sterilized milk.
According to some embodiments of the invention, the concentrating and sterilizing includes double-effect concentrating the mixed liquor (preferably homogenized mixed liquor or cooled mixed liquor) containing LNnT, and sterilizing at not less than 83 ℃ for 25 seconds to obtain concentrated sterilized milk.
According to some embodiments of the invention, wherein the parameters of the spray drying include: the air inlet temperature is 170-190 ℃, the air exhaust temperature is 80-90 ℃, the pump pressure is 150-250bar, and the negative pressure is-4.5-3.5 mbar.
According to some embodiments of the invention, wherein the parameters of the spray drying include: the air inlet temperature is 180 ℃, the air outlet temperature is 86 ℃, the pump pressure is 200bar, and the negative pressure is-4.0 mbar.
According to some embodiments of the invention, wherein the spray drying is spray drying with a drying tower.
According to some embodiments of the invention, wherein the high pressure pump has a pressure of 150-250bar (preferably 200 bar), the column negative pressure is-4.5 to-3.5 mbar (preferably-4.0 mbar).
According to some embodiments of the invention, wherein the spray drying comprises preheating the concentrated sterilized milk to 50-70deg.C (preferably 60-65deg.C), filtering (preferably with a filter having a pore size of 1-2 mm), and spray drying.
According to some embodiments of the invention, wherein the spray drying further comprises a secondary drying (preferably with a fluidized bed) after the spray drying, followed by cooling to 25-35 ℃ (preferably 30 ℃).
According to some embodiments of the invention, the dry mix comprises a homogeneous mixing of DHA and ARA with milk powder obtained after spray drying.
In summary, the invention provides a formula milk powder and a preparation method thereof. The formula milk powder has the following advantages:
the formula milk powder provided by the invention provides a solution for improving intestinal microenvironment health, such as reducing branched chain fatty acid (isovaleric acid). Meanwhile, the application of the combination of LNnT and probiotics in preparing foods for reducing branched chain fatty acids in intestinal tracts also provides a solution for relieving intestinal discomfort in the fields of children, teenagers and adults over 3 years old.
The breast milk infant formula milk powder containing LNnT and probiotics (bifidobacterium lactis BL-99) has the effect of reducing branched chain fatty acid (isovaleric acid) in intestinal tracts.
Drawings
FIG. 1 is a graph of the combined small batch fermentation of LNnT and probiotics to produce isovaleric acid as a percentage of total acid in a simulated infant intestinal environment.
Figure 2 is a graph of results of a combined small batch fermentation of LNnT and probiotics to produce isovaleric acid in a simulated infant intestinal environment.
Detailed Description
The following detailed description of the invention and the advantages achieved by the embodiments are intended to help the reader to better understand the nature and features of the invention, and are not intended to limit the scope of the invention.
Experimental method
The method for measuring the air pressure, the gas components and the short chain fatty acid content of the product after sample fermentation specifically comprises the following steps:
first, sample collection is carried out: a faecal sample of a 3-6 month old breast milk or formula fed infant was selected. Collecting one part of oral swab of each mother in the breast-feeding group, one part of fresh breast milk and one part of corresponding infant feces during the month-old period; one stool was collected for each infant in the artificial feeding group. Fresh feces were obtained from donors, transported to the laboratory in 4 hours with ice bags, fermented, and the short chain fatty acids of the fermented products were measured.
The measuring process is specifically as follows:
1. preparation of culture medium
(1) Preparing YCFA anaerobic basic culture medium, and packaging each 30ml of the culture medium into an anaerobic penicillin bottle with the total volume of 50ml for standby.
The YCFA anaerobic basal medium has the following formula (g/L): tryptone 10, yeast extract 2.5, L-cysteine hydrochloride 1, naCl 0.9, caCl 2 ·6H 2 O 0.009，KH 2 PO 4 0.45，K 2 HPO 4 0.45，MgSO 4 ·7H 2 O0.09；
The composition also comprises the following components: 1mL of resazurin (1 mg/mL), 2mL of heme (5 mg/mL), 200 μl of vitamin I solution;
wherein the vitamin I solution comprises (mg/mL): biotin (VH) 0.05, cobalamin (VB 12) 0.05, p-aminobenzoic acid 0.15, folic acid 0.25, pyridoxamine (VB 6) 0.75.
(2) The culture medium required in the examples of the present invention was formulated.
Before fermentation experiments, probiotics or prebiotics are added into the YCFA culture medium as required to form the culture medium required by the project. The final concentration of the added prebiotics in the experiment is 4 per mill; the final concentration of each added probiotic is 10 9 CFU/mL。
The probiotics and prebiotics added as referred to in the experiment are shown in table 1. Wherein each medium was divided into two cases of adding and not adding ETEC, and the total of 42 fermentation conditions was obtained. The final concentration of ETEC added was 10 10 CFU/mL。
TABLE 1 fermentation condition list
2. Strain activation and identification
Respectively taking bacterial strains BB12, YLGB-1496, HN019 and BL-99 bacterial powder, preparing into 10 in an anaerobic workstation 7 CFU/mL, concentration was measured using plate counting. Before preparing the culture medium, taking out the glycerol tube strain kept in a refrigerator at-80 ℃ and inoculating the glycerol tube strain into the MRS culture medium for activation, and then inoculating the activated strain liquid into the corresponding culture medium by using a syringe.
Taking bacterial strain ETEC (ATCC 35401) bacterial powder, preparing to 10 in an anaerobic workstation 10 CFU/mL, concentration was measured using plate counting.
3. In vitro fermentation
(1) Preparation of samples before fermentation:
accurately weighing 0.800+/-0.010 g of fresh feces, placing the fresh feces into one side of a stirring spoon of a feces pretreatment box, calculating according to the mass-volume ratio of 10%, and supplementing PBS buffer solution with corresponding volume. Vortex for about 5-10 minutes to thoroughly break up fecal debris and mix well with PBS buffer to prepare a uniform 10% fecal suspension (w/v). And standing the fecal pretreatment box on a table top, and filtering the suspension by two layers of filter screens for later use.
(2) Inoculating: in the anaerobic station, 0.5mL of the suspension (clarified side of pretreatment cassette) was aspirated with a 1mL syringe equipped with a 5-gauge needle, the penicillin bottle butyl rubber stopper was pierced, and the medium was injected.
Inoculation and dynamic sampling were all done in anaerobic workstations, with 5 biological replicates for each medium for breast feeding and artificial feeding groups, respectively.
The rest feces is as such, and the feces suspension can be split-packed as required, marked and frozen for other detection.
(3) Fermentation: the penicillin bottle is placed in a 37 ℃ incubator for static culture for 24 hours without disturbance. After the cultivation is finished, the small bottle is taken out, the cover is not opened, and the small bottle is directly frozen at-20 ℃ for detection.
4. Short chain fatty acid detection
Total short chain fatty acid concentrations, including acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, were measured using a gas chromatograph (9720, ark instruments, inc.). The method comprises the following specific steps:
(1) Preparation before sample injection: mu.L of the fermentation broth was aspirated using a sterile needle, placed in a 1.5ml centrifuge tube, 100. Mu.L of crotonic acid metaphosphoric acid solution was added, and the mixture was frozen at-30℃for 24 hours. After thawing, centrifugation was carried out at 10000rpm at 4℃for 3min, the supernatant was collected and filtered with a 0.22 μm filter (Millipore), 100. Mu.L of the sample extract was added to the cannula in the gas phase sample bottle, and after removing the bubbles by capping, the sample was loaded for analysis.
(2) The gas chromatograph conditions were as follows: chromatographic column: agilent FFAP 30m 0.25mm 0.25 μm; column temperature: heating to 180deg.C at 75deg.C at 20deg.C/min for 1min, heating to 220deg.C at 50deg.C/min for 1min; sample inlet: temperature: 250 ℃, sample injection amount: 1.0 μl, split ratio: (5:1); carrier gas: high purity nitrogen; flow rate: 2.5mL/min for 6.5min,2.8mL/min for 2L to 2.8mL/min for 2min; a detector: FID; temperature: 250 ℃; tail blowing: 20mL/min; hydrogen gas: 30mL/min; air: 300mL/min.
(3) Quantitative determination is carried out by using a peak area internal standard method, and automatic calculation is carried out by using built-in software of a workstation according to a standard curve equation internal standard method.
Example 1
This example provides a simulation of the combined small batch fermentation of LNnT and probiotics in an infant intestinal environment to produce isovaleric acid as a percentage of total acid, the results are shown in figure 1.
It can be seen that the combination of LNnT with probiotics was superior to the blank and four probiotic alone groups in all experimental groups. And in the formula group, the combination of LNnT and probiotics produces a lower percentage of isovaleric acid to total acid than LNnT.
Example 2
This example provides results simulating the combined small batch fermentation of LNnT and probiotics in an infant intestinal environment to produce isovaleric acid.
The results of simulating the combined small batch fermentation of LNnT and probiotics in an infant intestinal environment to produce isovaleric acid are shown in fig. 2. It can be seen that the combination of LNnT with probiotics is superior to the blank and four probiotics alone in all experimental groups.
The significant differences between the combination of LNnT and probiotic and LNnT and the P-values are shown in table 2. As can be seen from table 2, the combination of LNnT and probiotics significantly reduced isovaleric acid (P < 0.0001) compared to LNnT, showing the synergistic effect of the combination of both. There was no significant difference between LNnT and the combination of four probiotics, respectively, with a greater tendency to reduce isovaleric acid significance (p= 0.1254) for lnnt+bl-99 than for lnnt+bb 12.
TABLE 2
The combination of LNnT and probiotics (LNnT+BL-99 works best, HN019 and YLGB-1496 are the influence of E.coli) produced a lower percentage of isovaleric acid to total acid than LNnT and probiotics alone.
Example 3
Infant formula 1 (preparation 1000 kg) containing LNnT and probiotic composition:
1000 kg of raw milk, 320 kg of lactose, 25 kg of whey protein powder WPC80%, 175 kg of desalted whey protein powder D90 kg, 40 kg of corn oil, 50 kg of soybean oil, 140 kg of OPO structural fat, 27 kg of alpha-whey protein powder, 9 kg of beta-casein powder, 1 kg of anhydrous cream, 17 kg of fructo-oligosaccharide powder, 40 kg of galacto-oligosaccharide syrup, 2.5 kg of breast milk oligosaccharide LNnT, 13.75 kg of compound nutrient, 12 kg of DHA, 22 kg of ARA, 2 kg of soybean phospholipid, 1 kg of anhydrous cream and 0.1 kg of bifidobacterium lactis BL-99.
Wherein the compound nutrients comprise about 2.5 kg of compound vitamin nutrition package, about 0.75 kg of choline chloride nutrition package, about 6 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 1.5 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
Infant formula 2 (preparation 1000 kg) containing LNnT and probiotic composition:
2100 kg of raw milk, 250 kg of skim milk powder, 190 kg of lactose, 34% of whey protein powder WPC 50 kg, 90 kg of desalted whey powder D90 kg, 72 kg of OPO structural fat, 54 kg of soybean oil, 9 kg of corn oil, 45 kg of high oleic sunflower seed oil, 5 kg of alpha-whey protein powder, 1 kg of beta-casein powder, 25 kg of fructo-oligosaccharide powder, 40 kg of galacto-oligosaccharide syrup, 2 kg of soybean lecithin, 1 kg of anhydrous cream, 1 kg of breast milk oligosaccharide LNnT, 22.85 kg of compound nutrient, 12 kg of DHA, 14 kg of ARA, 0.4 kg of bifidobacterium lactis BL-99 and 0.65 kg of nucleotide.
Wherein the compound nutrients comprise about 1.5 kg of choline chloride nutrition package, about 16 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 0.85 kg of magnesium chloride nutrition package, and 3.5 kg of vitamin package, and the base material of each nutrition package is lactose.
Infant formula 3 (preparation 1000 kg) containing LNnT and probiotic composition:
1000 kg of raw milk, 250 kg of skim milk powder, 150 kg of lactose, 34% of whey protein powder WPC 50 kg, 90 kg of desalted whey powder D225 kg, 106 kg of OPO structural fat, 37 kg of soybean oil, 30 kg of corn oil, 10 kg of alpha-whey protein powder, 10 kg of beta-casein powder, 5 kg of fructo-oligosaccharide powder, 15 kg of galacto-oligosaccharide syrup, 4 kg of breast milk oligosaccharide LNnT, 11 kg of compound nutrient, 12 kg of DHA, 14 kg of ARA, 0.2 kg of bifidobacterium lactis BL-99 and 0.65 kg of nucleotide.
Wherein the compound nutrients comprise about 1.5 kg of compound vitamin nutrition package, about 0.75 kg of choline chloride nutrition package, about 5 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 0.75 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
The infant formula containing the LNnT and probiotic composition is specifically prepared by the following process:
1) Rough filtration of cow milk: the cow milk is subjected to coarse filtration and degassing by a balance cylinder, is preheated by a plate heat exchanger, and is separated from impurities by a separator.
2) Homogenizing and sterilizing cow milk: part of raw milk after removing impurities enters a homogenizer for homogenization and the other part is not homogenized, and the raw milk and the homogenized raw milk are mixed and enter a sterilizing system for sterilization.
3) Powder adding: the powder raw materials are metered according to the formula, then are added into a powder mixing tank in a unified way through an air conveying system, and are sucked into a vacuum mixing tank through a vacuum system;
4) Melting and oil preparing: placing the grease specified in the formula into an oil melting room according to the formula requirement, keeping the temperature of the oil melting room at 50-90 ℃, after the oil is melted, pumping the oil into a mixed oil storage tank, and pumping the mixed oil into the mixed oil tank through an oil pump according to the formula requirement;
5) Nutrient dissolution and addition: and respectively dissolving the nutrient packages such as calcium powder, vitamins, minerals and the like with purified water, and sequentially adding the dissolved nutrient packages into a mixing tank to obtain mixed feed liquid.
6) LNnT dissolution addition: and (3) dissolving the LNnT raw material with part of the mixed liquor in the step (5), and adding the dissolved LNnT raw material into a mixing tank to obtain the mixed liquor containing LNnT.
7) And (3) filtering: the mixed feed liquid containing LNnT is filtered by a filter screen, and physical impurities possibly brought in the raw materials are removed.
8) Homogenizing: homogenizing the mixed feed liquid by a homogenizer, mechanically treating the fat globules, and dispersing the fat globules into uniform fat globules.
9) Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling: cooling to below 20 ℃, temporarily storing in a pre-storing cylinder, entering the next working procedure within 6 hours, and starting the stirrer according to the set requirement.
10 Concentration sterilization: during production, double-effect concentration is used, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds. The discharge concentrations were 50% dry matter.
11 Concentrated milk storage, pre-heating filtration, spray drying: the concentrated milk is temporarily stored in a concentrated milk balance tank. Preheating to 60deg.C by scraper preheater, filtering with 1mm pore size filter, spray drying by high pressure pump, and agglomerating fine powder on top of tower or fluidized bed. Air inlet temperature: the temperature of exhaust is at 180 ℃ and 86 ℃, the pressure of the high-pressure pump is 200bar, and the negative pressure of the tower is about-4 mbar.
12 Fluidized bed drying and cooling: the powder from the drying tower is dried again by the fluidized bed (first stage) and then cooled to 30 ℃ by the fluidized bed (second stage).
13 Split charging: and weighing DHA, ARA or bifidobacterium longum subspecies YLGB1496 or bifidobacterium lactis BL-99 according to the formula requirement by personnel in a powder making workshop, sealing bags and packaging.
14 Dry blending): mixing the weighed DHA, ARA or bifidobacterium longum subspecies YLGB1496 with milk powder in a dry mixer.
15 Screening powder: the granularity of the milk powder is uniform through the vibrating screen, and the powder slag is scrapped.
16 Powder discharge: and (3) receiving powder by using a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room.
17 Powder) is added: and pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.
18 Packaging: 400 g of automatic packaging machine fills nitrogen for packaging. The oxygen content is lower than 1% when nitrogen is filled. 900 g of iron can is automatically filled with nitrogen and packaged, and the oxygen content is lower than 5%.
19 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine.
20 Inspection of the finished product: sampling and checking the packaged product according to a checking plan.
21 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
Process parameters
1) Parameters of milk collecting section
| Project | Control parameters |
| Raw milk storage temperature (. Degree. C.) | 4 |
| Raw milk storage time (from start of milk collection to end of pasteurization) (h) | 6 |
| Raw milk preheating temperature (DEG C) | 75 |
| Sterilization temperature (. Degree. C.) | 85 |
| Cooling temperature (DEG C) | 6 |
| Pasteurized milk storage temperature (. Degree. C.) | 4 |
| Pasteurized milk storage time (start pasteurization until pasteurized milk empty) (h) | 12 |
2) Parameters of pretreatment section
3) Parameters of concentration section
| Project | Infant formula with LNnT and probiotic composition |
| Feed amount (m 3/h) | 18.0 |
| Sterilization temperature (. Degree. C.) | 88 |
| Vacuum degree of effect body (bar) | -0.79 |
| Steam pressure (bar) | 8.5 |
| Triple effect evaporator temperature (DEG C) | 64 |
| Four-effect evaporator temperature (DEG C) | 60.5 |
| Five-effect evaporator temperature (DEG C) | 55.5 |
| Condensed water temperature (DEG C) | 51.5 |
| Refractometer for dry substance (%) of concentrated milk | 50 |
4) Parameters of drying section
| Project | Infant formula with LNnT and probiotic composition |
| Feed amount (kg/h) | 6500 |
| Concentrated milk preheating temperature (DEG C) | 72.5 |
| High pressure line pressure (bar) | 205 |
| Main air intake temperature (DEG C) | 180 |
| Exhaust temperature (DEG C) | 80 |
| Inlet air temperature (DEG C) of static fluidized bed | 47.5 |
| Air inlet temperature (DEG C) of A/B section of fluidized bed | 50 |
| Inlet air temperature (DEG C) of C section of fluidized bed | 30 |
| Fluidized bed section D air inlet temperature (DEG C) | 22.5 |
| Powder discharge temperature (. Degree. C.) | 30 |
5) Packaging parameters
5.1 Dry mixing section
| Project | Control parameters |
| Premixing time (min) | 20 |
| Dry mixing time (min) | 5 |
5.2 Packaging section
Claims (9)
1. The formula milk powder comprises 1000 parts of the total weight of the formula milk powder, and the formula milk powder comprises the following raw materials: 0.01-4.5 parts by weight of breast milk oligosaccharide, 890-3800 parts by weight of raw milk, 0-480 parts by weight of lactose, 0-540 parts by weight of desalted whey powder, 0-350 parts by weight of skimmed milk powder, 0-80 parts by weight of whey protein powder WPC, 34-120 parts by weight of whey protein powder WPC, 0-0.18 part by weight of probiotics, 0-170 parts by weight of structural grease OPO, 0-150 parts by weight of high oleic sunflower seed oil, 0-50 parts by weight of corn oil, 0-50 parts by weight of canola oil, 0-80 parts by weight of soybean oil, 0-45 parts by weight of alpha-lactalbumin, 0-23 parts by weight of beta-casein, 1-2.5 parts by weight of soybean lecithin, 0-30 parts by weight of fructo-oligosaccharide slurry, 0-90 parts by weight of anhydrous butter, 0-8 parts by weight of nucleotides, 1-5 parts by weight of vitamin, 0-3 parts by weight of choline chloride, 0-2 parts by weight of mineral A and 1-18 parts by weight of mineral B; wherein mineral A is selected from the group consisting of copper, iron, iodine, zinc, selenium, manganese, and magnesium, and mineral B is selected from the group consisting of mineral salts of one or more of copper, iron, iodine, zinc, selenium, manganese, and magnesiumA combination of mineral salts of one or more of calcium, phosphorus, sodium, and potassium; the breast milk oligosaccharide contains 0.01-4.5 parts by weight of breast milk oligosaccharide LNnT; the probiotics are selected from: one or more of Bifidobacterium infantis YLGB-1496, bifidobacterium animalis subspecies of milk HN019 and Bifidobacterium lactis BL-99; the probiotics content is 10 per gram of formula milk powder 6 -2×10 12 CFU。
2. The formula of claim 1 wherein the preparation materials further comprise: 0.20-2.04 parts of inositol, 0-0.65 part of taurine, 0.06-0.5 part of L-carnitine, 3-18 parts of DHA and 3-18 parts of ARA.
3. The formula of claim 1 wherein the vitamin nutrient is selected from the group consisting of vitamin a, vitamin D, vitamin E, vitamin K1, vitamin B2, vitamin B6, vitamin B12, niacinamide, folic acid, pantothenic acid, and biotin.
4. The formula of claim 1 wherein the milk oligosaccharide LNnT is present in an amount of 142.9-428.6mg/100g of powder per 100g of formula.
5. The formula of claim 4 wherein the milk oligosaccharide LNnT is present in an amount of 178.6-392.9mg/100g of powder per 100g of formula.
6. Formula according to claim 1, wherein the probiotic content is 10 per gram of formula 8 -2×10 10 CFU。
7. The formula according to any one of claims 1 to 6, wherein the formula is an infant formula for reducing branched short chain fatty acids.
8. The formula of claim 7 wherein the branched short chain fatty acid is isovaleric acid.
9. The method for preparing the formula milk powder according to any one of claims 1 to 8, wherein the method comprises the following steps: wet compounding, homogenizing, concentrating, sterilizing, spray drying, dry mixing and packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211528939.6A CN115769840B (en) | 2022-11-30 | 2022-11-30 | Formula milk powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211528939.6A CN115769840B (en) | 2022-11-30 | 2022-11-30 | Formula milk powder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115769840A CN115769840A (en) | 2023-03-10 |
| CN115769840B true CN115769840B (en) | 2024-03-08 |
Family
ID=85390900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211528939.6A Active CN115769840B (en) | 2022-11-30 | 2022-11-30 | Formula milk powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115769840B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
| CN114145353A (en) * | 2021-11-30 | 2022-03-08 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof |
| CN114208893A (en) * | 2021-11-30 | 2022-03-22 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof |
| CN114568526A (en) * | 2020-11-30 | 2022-06-03 | 内蒙古伊利实业集团股份有限公司 | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof |
-
2022
- 2022-11-30 CN CN202211528939.6A patent/CN115769840B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
| CN114568526A (en) * | 2020-11-30 | 2022-06-03 | 内蒙古伊利实业集团股份有限公司 | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof |
| CN114145353A (en) * | 2021-11-30 | 2022-03-08 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof |
| CN114208893A (en) * | 2021-11-30 | 2022-03-22 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115769840A (en) | 2023-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8454950B2 (en) | Maternal supplement | |
| CN114568526A (en) | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof | |
| CN114223729B (en) | Application of bifidobacterium longum subspecies infantis and breast milk oligosaccharide composition in formula milk powder | |
| CN114208893B (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN114145353A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN116172191A (en) | Nutritional composition and its application in preparing anti-inflammatory products | |
| CN114223728B (en) | Premature/low birth weight infant formula containing prebiotics and probiotics | |
| CN114128767A (en) | Milk protein partially hydrolyzed hypoallergenic infant formula containing breast milk oligosaccharides | |
| CN115769840B (en) | Formula milk powder and preparation method thereof | |
| CN115769841B (en) | Formula milk powder and preparation method thereof | |
| CN118077908A (en) | Combination of LNnT and probiotics and application thereof in preparation of composition for reducing branched-chain fatty acid in intestinal tract | |
| CN116114767A (en) | Dairy products and their use in the preparation of anti-inflammatory products | |
| CN115669732B (en) | Hypoallergenic infant partially hydrolyzed formula containing the breast milk oligosaccharide LNnT | |
| CN114568527A (en) | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof | |
| CN115918733A (en) | Formula milk powder and preparation method thereof | |
| CN115644431B (en) | Formula food containing breast milk oligosaccharide for premature infant and preparation method and application thereof | |
| CN115868544A (en) | Lactose-free formula food containing breast milk oligosaccharide LNnT and preparation method and application thereof | |
| CN115644430A (en) | Milk protein deep-hydrolyzed infant formula containing breast milk oligosaccharide LNnT | |
| CN114145356B (en) | Formula milk powder capable of improving immune response and preparation method and application thereof | |
| CN118077774A (en) | Formula milk powder capable of improving mineral absorption and preparation method thereof | |
| CN118203051A (en) | Infant formula milk powder capable of promoting protein absorption and preparation method thereof | |
| US20220256904A1 (en) | Process for manufacturing a fermented infant formula product | |
| CN115804410A (en) | Infant formula containing prebiotic composition for promoting growth of Bifidobacterium longum subspecies of infants YLGB-1496 | |
| CN117652576A (en) | Formula milk powder with immunoregulation function activity and preparation method and application thereof | |
| CN117617313A (en) | A special medical infant food containing DHA easy to digest and absorb |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |